NWPF

News ArchivesRead News

News Update for the Week of 4.6.20

Monday April 06, 2020
Finding Resilience: People with Parkinson's Face Unique Circumstances Related to the COVID-19
Journal of Parkinson's Disease via MedicalXpress
Experts in researching Parkinson's recently outlined the importance of resilience among people with Parkinson's during the COVID-19 crisis. Their observations were published in Journal of Parkinson's Disease.
"Resilience, or the ability to maintain or quickly recover mental health during and after times of adversity, can protect against the detrimental effects of stress. Mindfulness-based interventions can reduce stress, and they see opportunities for web-based solutions to help reduce anxiety and depression, and also reduce social isolation*."
*NW Parkinson's offers FREE Mindful Compassion Classes, including tomorrow's first in a new six-week series. Register here!
-
Montana Expands Access To Suicide, Mental Health Hotlines During COVID-19 Crisis
Montana Public Radio
"The Montana State Health Department is "expanding hours and staffing of hone lines for mental health therapy and suicide prevention. This comes amid a surge of requests from Montanans seeking emotional support during the ongoing coronavirus crisis.
If you’re losing sleep, feeling unusually anxious, lonely, angry or depressed, you’re not alone. The state health department is expanding call-in hours to what’s called the Montana Warmline, 'a real human connection for people that might be struggling emotionally'. Warmline hours now run from 8 a.m. to 9 p.m. MT Monday to Friday, and 12 p.m. to 9 p.m. MT on Saturday and Sunday.
-
Excessive Daytime Sleepiness Therapy in People with Parkinson's Meets Phase 2 Primary Efficacy End Point
American Journal of Managed Care
"Theranexus, a pharmaceutical company, announced this week that its phase 2 trial for THN102 (modafinil/flecainide) in people with Parkinson'smet its primary efficacy end point of significantly increasing the proportion of patients no longer suffering from excessive daytime sleepiness (EDS)." Approximately 40% of people with Parkinson's are affected by EDS.
-
Long-Term Use of Isradipine Does Not Slow
Parkinson's Progression
Annals of Internal Medicine via Medical Xpress
"Isradipine, a dihydropyridine calcium-channel blocker approved for the treatment of hypertension, has been shown to be neuroprotective in animal models Parkinson's."
A recent study suggests that long-term intervention. Researchers discussed the results from their multicenter, randomized, parallel-group, double-blind, placebo-controlled trial in Annals of Internal Medicine.
-
Therapy Fights Depression for People with Parkinson’s
Futurity via Neurology Journal
People with Parkinson’s who engage in cognitive behavioral therapy are more likely to overcome depression and anxiety, according to a new study. “This study suggests that the effects of the cognitive behavioral therapy last long beyond when the treatment stopped and can be used alongside standard neurological care to improve global Parkinson’s outcomes.”